The aim of the present study was to test a possible effect of the monoamine oxidase A (MAOA) and serotonin receptor 2A (5-HT-2A) gene variants on the antidepressant activity of fluvoxamine and paroxetine in a sample of major (n l 248) and bipolar (n l 195) depressives, with or without psychotic features. A total of 443 inpatients were treated with 300 mg fluvoxamine (n l 307) or 20-40 mg paroxetine (n l 136) for 6 wk. The severity of depressive symptoms was assessed weekly with the Hamilton Rating Scale for Depression (HAMD). Allele variants were determined in each subject using a PCR-based technique. We observed a marginal association between 5-HT-2A variants and antidepressant response while MAOA genotypes were not associated. Possible stratification factors, such as sex, diagnosis, presence of psychotic features, HAMD scores at baseline, pindolol augmentation and SSRIs plasma levels did not significantly influence the observed results. The investigated MAOA and 5-HT-2A gene variants, therefore, do not seem to play a major role in SSRI antidepressant activity.
Introduction
Antidepressant response is thought to be influenced by genetic factors (O 'Reilly et al., 1994 ; Pare et al., 1962 ; Sederer, 1986) . Selective serotonin reuptake inhibitors (SSRIs) are the most widely used antidepressant treatment and they block the serotonin (5-HT) transporter as a first step of their action. The serotonergic pathway is therefore a candidate in the search for liability genes. The functional polymorphism at the 5-HT transporter promoter region (5-HTTLPR) has been repeatedly associated with the efficacy of various antidepressant treatments (Benedetti et al., 1999 ; Kim et al., 2000 ; Pollock et al., 2000 ; Smeraldi et al., 1998 ; Zanardi et al., 2000) . Preliminary evidence suggests that also the tryptophan hydroxylase (TPH) gene variants possibly influence antidepressant response (Serretti et al., 2001a,b) . As antidepressant response is a complex trait, further genes are likely to be involved in the serotonergic pathway (Frankel and Schork, 1996) . We therefore selected further functional polymorphisms of genes coding for proteins that are involved in the mechanism of action of SSRIs.
Monoamine oxidase A (MAOA) is one of the key enzymes in the metabolism of 5-HT (Berry et al., 1994) . MAOA inhibitors, (I-MAO) increasing the levels of 5-HT among other neurotransmitters, are effective in the pharmacotherapy of depression (Berry et al., 1994) . It is also believed that the mechanism of action of SSRIs is influenced by MAOA at the nerve terminal level, where it is reported to interact with the 5-HT transporter in modulating serotonergic tone (Maes and Meltzer, 1995) .
MAOA is encoded by a single gene arranged on the short arm of the X chromosome at Xp11n23 (Sabol et al., 1998) and animal models suggest that the deletion of the MAOA gene causes behavioural alterations (Cases et al., 1995) . Several different polymorphisms in the human MAOA gene have been identified, including variable number tandem repeats (VNTR) in the first intron (Hinds et al., 1992) , a dinucleotide repeat in the second intron (Black et al., 1991) , a G to T substitution at position 941 (at the third base of codon 297\exon 8) that results in a Fnu4H1 restriction length polymorphism (RFLP), a T to A substitution at position 1077 and a T to C substitution at position 1460 (Brunner et al., 1993 ; Hotamisligil and Breakefield, 1991 ; Hsu et al., 1988) . A marginally significant association between Fnu4H1 and MAOA activity levels has been described ; more specifically, this MAOA RFLP has been associated with high MAOA activity in vitro when the Fnu4H1 allele is present (Hotamisligil and Breakefield, 1991) . More interestingly, the polymorphism located 1n2 kb upstream of the MAOA coding sequences has been shown to affect the transcriptional activity of the MAOA gene promoter. This mutation consists of a 30 bp repeat, alleles with 4 copies of the repeat sequence are transcribed 2-10 times more efficiently than those with 3 copies of the repeat (Denney et al., 1999 ; Sabol et al., 1998) .
Studies seeking associations between MAOA and mood disorders furnished mixed results, as preliminary positive findings were not subsequently replicated (Craddock et al., 1995 ; Furlong et al., 1999 ; Kawada et al., 1995 ; Kunugi et al., 1999 ; Lim et al., 1995 ; Lin et al., 2000 ; Nothen et al., 1995 ; Parsian and Todd, 1997 ; Preisig et al., 2000 ; Rubinsztein et al., 1996 ; Schulze et al., 2000 ; Turecki et al., 1999) .
A further candidate is the gene coding for the human 5-HT receptor 2A (5-HT-2A). Many actions of serotonergic agents were attributed to a 5-HT-2A receptor that appear to play a role in appetite control, thermoregulation and sleep (Burnet et al., 1995) . Chronic administration of tricyclic or I-MAO antidepressants result in downregulation of the 5-HT-2 receptors and also SSRIs have been associated with a decreased responsiveness of 5-HT-2 ; finally 5-HT-2A antagonists such as mirtazapine, nefazodone, ritanserin possess antidepressant properties (Glennon and Dukat, 1995) .
Its coding gene is located on chromosome 13 (13q14-21) and consists of three exons spanning more than 20 kb. Polymorphisms of the 5-HT-2A gene have been extensively investigated in psychiatric disorders (Arranz et al., 1995 ; Williams et al., 1996) but much less in mood disorders. An excess of the silent T\C mutation in amino acid 102 (T102C) has been reported in major depressive disorder (Zhang et al., 1997) , but mainly negative studies followed Gutierrez et al., 1997 ; Mahieu et al., 1997 ; Massat et al., 2000 ; Serretti et al., 1999) . Other less studied polymorphisms in the 5-HT-2A gene have been identified, including some amino-acid substitutions (Erdmann et al., 1996 ; Ozaki et al., 1996) .
In the present paper we hypothesized that MAOA 30 bp and 5-HT-2A T102C, C-1420T variants could be involved in individual responsiveness to antidepressant therapy with SSRIs in mood disorders.
Methods

Sample
A total of 443 in-patients, consecutively admitted to the Mood Disorder Centre, Department of Psychiatry at the Institute H. San Raffaele, Milan, were included in this study (age l 51n41p13n41 yr ; onset l 36n46p12n97 yr ; female\male : 297\146 ; bipolars\ major depressives l 195\248). Lifetime diagnoses were assigned by trained psychiatrists and supervised by an independent senior psychiatrist on the basis of unstructured clinical interviews and medical records, according to DSM-IV criteria and following a best-estimate procedure (Leckman et al., 1982) . The presence of any concomitant Axis I diagnosis, major depressive single episode, together with somatic or neurological illnesses impairing psychiatric evaluation represented exclusion criteria. Subjects had not taken non-reversible monoamine oxidase inhibitors or slow-release neuroleptics for at least 1 month before entering the study. All patients were evaluated at baseline and weekly thereafter until week 6 using the 21-item Hamilton Rating Scale for Depression (HAMD) (Hamilton, 1967) administered by trained senior psychiatrists blind to genetic data and to treatment. Subjects for the present study have been treated in the context of previous trials under double-blind conditions (Serretti et al., 2001a,b ; Smeraldi et al., 1998 ; Zanardi et al., 2000) , including 217 subjects of fluvoxamine studies (Serretti et al., 2001a ; Smeraldi et al., 1998) and 121 of paroxetine studies (Serretti et al., 2001b ; Zanardi et al., 2000) , where 5-HTTLPR and TPH variants were studied in 105 new subjects. Briefly, after a 7-d washout period, fluvoxamine or paroxetine were titrated to reach 300 mg or 20-40 mg daily, respectively from day 8 until the end of the trial. Pindolol, 2n5 mg t.i.d. was blindly added to approximately one third of the sample randomly selected (149\443). Concomitant psychotropic drugs were not allowed, except flurazepam at bedtime (up to 45 mg) or lithium maintenance (n l 72\443). A decrease in HAMD scores to 8 or less, with delusion factor equal to 0 (items 2, 15, 20) (Bech et al., 1993 ; Bellini et al., 1992 ; Sobin and Sackeim, 1997) were considered the response criterion. After the procedure had been fully explained to all subjects, written informed consent was obtained. Plasma drug levels were determined by high-performance liquid chromatography after 2 wk of stable daily dose (Lucca et al., 1994) . Four patients with fluvoxamine and five with paroxetine plasma levels exceeding the mean value of the sample p1n96 .. were removed from the study to avoid the possibility that extreme differences in the bioavailability of the drug could influence the clinical response.
DNA analysis
EDTA-anticoagulated venous blood samples were drawn from all probands and DNA was extracted from leucocytes by NaCl precipitation (Lahiri and Nurnberger, 1991) . Polymerase chain reaction (PCR) was performed with the following primers : for MAOA : 5h-GGACCTGGGCAG-TTGTGC-3h, and 5h-CCCAGGCTGCTCCAGAAA-3h ; for 5-HT-2A T102C : 5h-CGC CCG CCG CGC CCC GCG CCC GTC CCG CCG TCT GCT ACA AGT TCT GGC TT-3h, and 5h-CTG CAG CTT TTT CTC TAG GG3h ; for 5-HT-2A for C-1420T : 5h-AAG CTG CAA GGT AGC AAC AGC-3h and 5h-AAC CAA CTT ATT TCC TAC CAC-3h. PCR products were analysed as described previously (Sabol et al., 1998 ; Serretti et al., 2000a) ; 416 subjects were typed for MAOA ; 340 subjects were typed for T102C and 408 for C-1420T. MAOA marker is located on the X chromosome, therefore we separately analysed males and females. MAOA variants were pooled in short (2, 3 and 3n5) and long (4 and 5) variants (Deckert et al., 1999) . The sample was in Hardy-Weinberg equilibrium (MAOA, χ# l 0n77, p l 0n38 ; T102C, χ# l 0n80, p l 0n37), except for the 5-HT-2A C-1420T variant ( χ# l 25n05, p l 0n001) due to the small sample of homozygous mutated subjects.
Statistical analysis
Seven HAMD score measurements (baseline and 6 wk) were analysed. Random regression model (RRM) (Elkin et al., 1995 ; Gibbons et al., 1993 ; Serretti et al., 2000b) was used for the present study. It was implemented in the computer program  available at http :\\www.uic.e du\"hedeker\mix.html (Hedeker and Gibbons, 1996) . The HAMD total score was included as dependent variable in the RRM model, time and intercept were random effects, and each independent clinical and genetic variable, plus the interaction of this variable with time were considered fixed effects and individually tested. In the case of a clinical variable showing a significant effect, interactions with genetic variables were calculated. In order to obtain an approximate linearity we used the transformation ln (timej1).
An ' intent-to-treat ' analysis was carried out for all patients who had a baseline assessment and at least one assessment after randomization, with the last observation carried forward on the HAMD. ANOVA, ANCOVA, t test and χ# were used to compare distribution of clinical variables across genotypes. All p values were 2-tailed, and statistical significance was set at p 0n017 (Bonferronicorrected for three genotypes). The haplotype analysis ' E H package ' was used for the analysis of disequilibrium between 5-HT-2A (T102C) and (C-1420T) polymorphisms (Terwilliger and Ott, 1994) .
Exact power analyses for the RRM technique are not available to date, however approximating it to traditional parametric analyses, we calculated a power of 0n80 to detect a small effect size (d l 0n38 -depending on the frequency of the risk allele, considering an α value of 0n017 two tailed) which corresponded to a difference of approx. 4n2 points on the HAMD between two groups (Cohen, 1988) .
Results
A detailed description of the clinical outcome of the sample has been previously reported (Serretti et al., 2001a,b ; Smeraldi et al., 1998 ; Zanardi et al., 2000) . A brief description of the pooled sample is illustrated in Table 1 . MAOA variants showed no significant association with both clinical features and antidepressant response (Table 2 ). For 5-HT-2A (T102C) we observed a marked difference in gender distribution (p l 0n0002) and lithium maintenance distribution (p l 0n003) (Table 3) . No difference was observed for the remaining variables (Table 4 ). The 5-HT-2A C-1420T*T\T genotype result is associated with higher levels of HAMD at baseline and worse response (Table 5) ; the result on the final HAMD was robust to the covariance with baseline (F l 8n33, p l 0n0003). However, this finding was due to a very small number of subjects and it was not observed in the categorical and RRM analyses (Table 5) .
Possible stratification factors, such as sex, diagnosis, presence of psychotic features, depressive symptomatology at baseline, pindolol augmentation, SSRI and SSRI plasma levels did not significantly influence the observed results. Haplotype analysis revealed a significant disequilibrium between the two 5-HT-2A markers ( χ# l 12n33, d.f. l 1, p l 0n0004).
RRM results
The time-course of antidepressant response was investigated using RRM analysis (Table 6 ). We observed a significant effect of time, indicating an overall symp- tomatic improvement during the trial. Presence of suicidal behaviour and psychotic features were associated with higher HAMD baseline scores.
Furthermore, we performed the analysis on the effect of independent variables on the HAMD time-course. Gender, diagnosis, age at the time of the study and age at 
Data are expressed as meansp.. Gender and lithium distribution differed among the genotype groups. 
Data are expressed as meansp.. (see text for comments). onset did not significantly influence antidepressant treatment outcome while subjects with psychotic features and higher HAMD baseline scores showed a more rapid decrease of depressive symptomatology. Pindolol augmentation and lithium maintenance showed marginal associations with time-course. No significant association with increased severity at baseline or time-course was observed for any polymorphism.
Discussion
In the present sample, MAOA and 5-HT-2A variants were not associated with SSRI treatment outcome, even considering other clinical variables, such as sex, diagnosis, presence of psychotic features, HAMD at baseline, SSRI plasma level and pindolol augmentation.
Pharmacogenetic studies have multiplied in recent years due to the impact that such studies may have in everyday clinical practice once reliable predictors could be identified (Pickar and Rubinow, 2001 ; VeenstraVanderWeele et al., 2000) . Promising results have been reported, the 5-HTTLPR short variants have been previously associated with a slower response to various antidepressant treatments (Benedetti et al., 1999 ; Pollock et al., 2000 ; Smeraldi et al., 1998 ; Zanardi et al., 2000) , though not univocally (Kim et al., 2000) . A second polymorphism, located in the gene coding for TPH seem to be associated with SSRI response (Serretti et al., 2001a) . The two polymorphisms explained respectively 5 and 7 % of the variance and, although our data exclude an influence of MAOA and 5-HT-2A variants on SSRI antidepressant activity, further polymorphisms or control mechanisms should be investigated. Our centre is currently testing a number of possible candidate genes within both the dopaminergic and serotonergic systems. In the present study we excluded major associations with MAOA and 5-HT-2A variants. The marginal association observed for the C-1420T variant was not confirmed by complementary analyses with RRM and by the flanking T102C polymorphism, we may, therefore, provisionally consider this as a false positive. Moreover the C-1420T variant was not in Hardy-Weinberg equilibrium in our sample. This is usually due to a variety of reasons (Nielsen et al., 1998) , we dealt with this problem by double-checking laboratory data, the results proved reliable, we also checked the distribution in other subjects not included in the present study for a total of 386 controls and 909 affected subjects and the departure was still observed. Association with the disease is another frequent cause of departure from Hardy-Weinberg equilibrium, but this was not the case (Serretti A, unpublished data) . We may, therefore, hypothesize an ethnic bias ; however, although being Italian is characterized by a substantial genetic homogeneity (Gasparini et al., 1997) , our sample should not be affected by such a bias.
The power of our sample was sufficient to detect a difference of 4n2 points at the HAMD, allowing us to reduce, though not eliminate, the risk of a false-negative finding. Most studies performed in tertiary care settings, like the present one, may be biased because the use of selection criteria limits the extent to which the sample is representative (Maj et al., 1998) . Therefore, it may be argued that patients, as evidenced by the high rate of delusional subjects, have a more severe psychiatric disturbance than in the population-based sample. However, this helps to reduce the inclusion of non-genetic cases, because milder forms of the disease are more likely to be phenocopies (Tsuang and Faraone, 1990) . In the present paper we used two different SSRIs, this could introduce a bias, however fluvoxamine and paroxetine share the same mechanism of action and we previously observed a substantial similarity between them regarding genetic influences (Serretti et al., 2001a,b) , finally, covariance analysis excluded the bias in the present sample.
In conclusion, variants of the MAOA and 5-HT-2A T102C and A-1420G polymorphisms did not influence the antidepressant response in our sample.
